|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM129A |
Gene summary for FAM129A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM129A | Gene ID | 116496 |
| Gene name | niban apoptosis regulator 1 | |
| Gene Alias | C1orf24 | |
| Cytomap | 1q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | A0A024R978 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 116496 | FAM129A | P54T-E | Human | Esophagus | ESCC | 1.27e-11 | 3.11e-01 | 0.0975 |
| 116496 | FAM129A | P57T-E | Human | Esophagus | ESCC | 3.71e-19 | 4.81e-01 | 0.0926 |
| 116496 | FAM129A | P61T-E | Human | Esophagus | ESCC | 3.72e-07 | 2.22e-01 | 0.099 |
| 116496 | FAM129A | P62T-E | Human | Esophagus | ESCC | 3.36e-40 | 8.16e-01 | 0.1302 |
| 116496 | FAM129A | P74T-E | Human | Esophagus | ESCC | 3.90e-03 | 1.19e-01 | 0.1479 |
| 116496 | FAM129A | P75T-E | Human | Esophagus | ESCC | 3.92e-06 | 1.19e-01 | 0.1125 |
| 116496 | FAM129A | P76T-E | Human | Esophagus | ESCC | 1.16e-07 | 2.61e-01 | 0.1207 |
| 116496 | FAM129A | P79T-E | Human | Esophagus | ESCC | 2.69e-07 | 2.39e-01 | 0.1154 |
| 116496 | FAM129A | P82T-E | Human | Esophagus | ESCC | 2.64e-13 | 4.01e-01 | 0.1072 |
| 116496 | FAM129A | P84T-E | Human | Esophagus | ESCC | 4.67e-03 | 3.35e-01 | 0.0933 |
| 116496 | FAM129A | P89T-E | Human | Esophagus | ESCC | 1.18e-04 | 6.55e-01 | 0.1752 |
| 116496 | FAM129A | P91T-E | Human | Esophagus | ESCC | 7.86e-10 | 1.09e+00 | 0.1828 |
| 116496 | FAM129A | P107T-E | Human | Esophagus | ESCC | 4.65e-22 | 5.63e-01 | 0.171 |
| 116496 | FAM129A | P127T-E | Human | Esophagus | ESCC | 3.01e-06 | 1.32e-01 | 0.0826 |
| 116496 | FAM129A | P128T-E | Human | Esophagus | ESCC | 1.86e-25 | 7.51e-01 | 0.1241 |
| 116496 | FAM129A | P130T-E | Human | Esophagus | ESCC | 7.42e-17 | 5.66e-01 | 0.1676 |
| 116496 | FAM129A | C04 | Human | Oral cavity | OSCC | 3.42e-18 | 6.08e-01 | 0.2633 |
| 116496 | FAM129A | C21 | Human | Oral cavity | OSCC | 1.47e-15 | 6.08e-01 | 0.2678 |
| 116496 | FAM129A | C30 | Human | Oral cavity | OSCC | 2.26e-22 | 9.25e-01 | 0.3055 |
| 116496 | FAM129A | C43 | Human | Oral cavity | OSCC | 9.66e-07 | 2.17e-01 | 0.1704 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM129A | SNV | Missense_Mutation | c.2728G>A | p.Asp910Asn | p.D910N | Q9BZQ8 | protein_coding | deleterious_low_confidence(0.05) | possibly_damaging(0.624) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FAM129A | SNV | Missense_Mutation | c.2182C>G | p.Pro728Ala | p.P728A | Q9BZQ8 | protein_coding | tolerated_low_confidence(0.86) | benign(0.015) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FAM129A | SNV | Missense_Mutation | c.71C>T | p.Ala24Val | p.A24V | Q9BZQ8 | protein_coding | tolerated(1) | benign(0.003) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| FAM129A | SNV | Missense_Mutation | c.203G>C | p.Gly68Ala | p.G68A | Q9BZQ8 | protein_coding | tolerated(0.18) | benign(0.337) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| FAM129A | insertion | Frame_Shift_Ins | novel | c.603_604insGGTGCCTTGCCTCTGTGTGG | p.Tyr202GlyfsTer9 | p.Y202Gfs*9 | Q9BZQ8 | protein_coding | TCGA-A8-A09T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | ||
| FAM129A | insertion | Nonsense_Mutation | novel | c.1717_1718insAGAGGGCTGCACCTTAGGTTCTGACCCCAT | p.Met573delinsLysArgAlaAlaProTerValLeuThrProLeu | p.M573delinsKRAAP*VLTPL | Q9BZQ8 | protein_coding | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| FAM129A | SNV | Missense_Mutation | c.1885G>A | p.Glu629Lys | p.E629K | Q9BZQ8 | protein_coding | tolerated(0.21) | benign(0.077) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| FAM129A | SNV | Missense_Mutation | rs769217969 | c.2777N>T | p.Ser926Leu | p.S926L | Q9BZQ8 | protein_coding | tolerated_low_confidence(0.12) | benign(0.006) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| FAM129A | SNV | Missense_Mutation | rs562448693 | c.134N>A | p.Arg45His | p.R45H | Q9BZQ8 | protein_coding | tolerated(0.16) | probably_damaging(0.938) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FAM129A | SNV | Missense_Mutation | c.560T>G | p.Phe187Cys | p.F187C | Q9BZQ8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |